PCAS key Figures (2016)

€192

million


Consolidated net sales

7%


Of net sales dedicated to R&D

7


Production sites

€27.3

million


EBITDA
Earnings before interest, taxes, depreciation and amortization



982


Employees

PCAS sales
/ by geographic zone /

  • 37%
    Europe
  • 31%
    France
  • 14%
    Asian Pacific
  • 15%
    North America
  • 3%
    Others

PCAS sales
/ by market /

  • 43%
    Pharma Synthesis Exclusive & Pharma Chemicals
  • 25%
    Pharma Sythesis Generic APls
  • 16%
    Performance Fine Chemicals
  • 16%
    Advanced Specialties

Breakdown of PCAS
Share Capital at
12/31

  • 44.7%
    Public
  • 29.5%
    Eximium
  • 14.7%
    C. Moretti / Anblan
  • 8.7%
    Treasury stocks*
  • 2.4%
    Management
In millions of euros20152015
restated **
2016
Net sales179.1179.1192.0
Pharmaceutical synthesis
Fine specialty chemicals
120.8
58.3
120.8
58.3
130.0
62.0
EBITDA*27.027.027.3
EBITDA margin15.1%15.1%14.2%
EBIT*15.615.616.2
EBIT margin8.7%8.7%8.4%
Other operating income and expenses
Financial result
Taxes
0.4
-5.1
-2.1
-3.1
-5.1
-1.5
-2.3
-6.4
-0.9
Net Income8.85.96.6
Equity
Net debt
89.1
34.7
97.0
48.7
Gearing0.390.50
Net asset attributable to the Group per share6.416.85

* Including research tax credit of €3.1 million in 2015 and €3.3 million in 2016.

** Excluding the effect of non recurring insurance revenue net of tax

Key adjusted per share figures

In euros20152016
Highest price8.0014.06
Lowest price3.606.75
Price at the end of December7.9714.02
Net sales11.8312.68
Current operating income1.031.07
Net profit attributable to the Group0.590.45

PCAS shares are listed on Nyse Euronext, compartment C. The shares have been continuously listed since October 17, 1996 and are subject to a liquidity contract with Kepler Cheuvreux.

PCAS 2016 share price

Contacts: